GAIN THERAPEUTICS INC (GANX) Fundamental Analysis & Valuation

NASDAQ:GANX • US36269B1052

Current stock price

2.04 USD
-0.05 (-2.39%)
At close:
2.0132 USD
-0.03 (-1.31%)
Pre-Market:

This GANX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GANX Profitability Analysis

1.1 Basic Checks

  • GANX had negative earnings in the past year.
  • In the past year GANX has reported a negative cash flow from operations.
  • GANX had negative earnings in each of the past 5 years.
  • In the past 5 years GANX always reported negative operating cash flow.
GANX Yearly Net Income VS EBIT VS OCF VS FCFGANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • GANX has a Return On Assets of -189.07%. This is amonst the worse of the industry: GANX underperforms 87.02% of its industry peers.
  • GANX's Return On Equity of -503.05% is on the low side compared to the rest of the industry. GANX is outperformed by 77.71% of its industry peers.
Industry RankSector Rank
ROA -189.07%
ROE -503.05%
ROIC N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
GANX Yearly ROA, ROE, ROICGANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600

1.3 Margins

  • GANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GANX Yearly Profit, Operating, Gross MarginsGANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. GANX Health Analysis

2.1 Basic Checks

  • GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GANX has been increased compared to 1 year ago.
  • The number of shares outstanding for GANX has been increased compared to 5 years ago.
  • The debt/assets ratio for GANX has been reduced compared to a year ago.
GANX Yearly Shares OutstandingGANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
GANX Yearly Total Debt VS Total AssetsGANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • GANX has an Altman-Z score of -9.89. This is a bad value and indicates that GANX is not financially healthy and even has some risk of bankruptcy.
  • GANX's Altman-Z score of -9.89 is on the low side compared to the rest of the industry. GANX is outperformed by 73.45% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that GANX is not too dependend on debt financing.
  • GANX has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: GANX underperforms 62.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -9.89
ROIC/WACCN/A
WACC9.54%
GANX Yearly LT Debt VS Equity VS FCFGANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

  • GANX has a Current Ratio of 1.79. This is a normal value and indicates that GANX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of GANX (1.79) is worse than 79.46% of its industry peers.
  • A Quick Ratio of 1.79 indicates that GANX should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.79, GANX is doing worse than 77.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.79
GANX Yearly Current Assets VS Current LiabilitesGANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GANX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 33.70% over the past year.
EPS 1Y (TTM)33.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GANX will show a small growth in Earnings Per Share. The EPS will grow by 7.19% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.63%
EPS Next 2Y-3.27%
EPS Next 3Y-10.87%
EPS Next 5Y7.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 2033 100M 200M 300M 400M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. GANX Valuation Analysis

4.1 Price/Earnings Ratio

  • GANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year GANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GANX Price Earnings VS Forward Price EarningsGANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GANX Per share dataGANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as GANX's earnings are expected to decrease with -10.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.27%
EPS Next 3Y-10.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GANX Dividend Analysis

5.1 Amount

  • No dividends for GANX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GANX Fundamentals: All Metrics, Ratios and Statistics

GAIN THERAPEUTICS INC

NASDAQ:GANX (4/22/2026, 8:00:01 PM)

Premarket: 2.0132 -0.03 (-1.31%)

2.04

-0.05 (-2.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-12
Inst Owners19.11%
Inst Owner Change-0.03%
Ins Owners2.37%
Ins Owner Change0%
Market Cap86.17M
Revenue(TTM)N/A
Net Income(TTM)-18.59M
Analysts85.45
Price Target7.75 (279.9%)
Short Float %8.02%
Short Ratio4.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.1%
Min EPS beat(2)-10.66%
Max EPS beat(2)12.85%
EPS beat(4)3
Avg EPS beat(4)16.46%
Min EPS beat(4)-10.66%
Max EPS beat(4)41.18%
EPS beat(8)5
Avg EPS beat(8)-0.57%
EPS beat(12)6
Avg EPS beat(12)-7.64%
EPS beat(16)8
Avg EPS beat(16)-4.54%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 23.31
P/tB 24.15
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS0.09
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -189.07%
ROE -503.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 1.79
Altman-Z -9.89
F-Score3
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)81.72%
Cap/Depr(5y)179.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-1.63%
EPS Next 2Y-3.27%
EPS Next 3Y-10.87%
EPS Next 5Y7.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.3%
OCF growth 3YN/A
OCF growth 5YN/A

GAIN THERAPEUTICS INC / GANX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GAIN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to GANX.


What is the valuation status of GAIN THERAPEUTICS INC (GANX) stock?

ChartMill assigns a valuation rating of 0 / 10 to GAIN THERAPEUTICS INC (GANX). This can be considered as Overvalued.


What is the profitability of GANX stock?

GAIN THERAPEUTICS INC (GANX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GAIN THERAPEUTICS INC?

The Earnings per Share (EPS) of GAIN THERAPEUTICS INC (GANX) is expected to decline by -1.63% in the next year.